ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Extracellular Vesicle-Transferred ATP-Citrate Lyase Induces Monocyte Differentiation Toward Tumor-Associated Macrophages and Fuels Hepatocellular Carcinoma Progression.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- New insights into the ACLY-mediated metabolic and epigenetic interplay in macrophages.Journal of enzyme inhibition and medicinal chemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Tumor-associated macrophages (TAMs) arise from monocytes and represent major contributors to the immunosuppressive microenvironment of solid tumors. However, the environmental cues that govern TAM differentiation and immunosuppressive activity remain incompletely understood. Here we demonstrate that hepatocellular carcinoma (HCC) cells secrete extracellular vesicles (EVs) that are preferentially taken up by monocytes, inducing their differentiation to TAMs characterized by a distinct immune-inhibitory signature. Mechanistically, HCC-derived EVs encapsulate the lipogenic enzyme ATP-citrate lyase (ACLY), promote palmitate biosynthesis in targeted monocytes, thereby enhancing the S-palmitoylation and stability of multiple immune checkpoint proteins. To validate this, we synthesized liposomal vesicles (LVs) decorated with an EV-marker protein CD81, which mimicked the targeting specificity of endogenous EVs for monocytes and differentiated macrophages. When loaded with ACLY proteins as interior cargo, these LVs were sufficient to induce immunosuppressive TAMs and promote HCC progression. Conversely, CD81-decorated LVs encapsulating the ACLY inhibitor SB204990 markedly reduced the TAM-mediated immunosuppressive activity, leading to restrained HCC progression. Importantly, we further demonstrated that targeting EV-transferred, TAM-specific ACLY represents a promising strategy to enhance immunotherapeutic efficacy without notable side effects, particularly when combined with anti-PD-1/PD-L1 antibodies for HCC treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.